Rubraca
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Rubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations or other homologous recombination gene alterations. PARP is an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events. PARP inhibitors act by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death. Tumor cells with BRCA1/2 gene mutations are dependent on PARP for DNA damage repair, and PARP inhibition selectively kills BRCA1- or BRCA2-deficient cells. As DNA repair is inhibited by PARP inhibitors, they are often sequenced after a cytotoxic chemotherapy which works by damaging DNA.
TABLE OF CONTENTS
4 Product Profiles
4 Rubraca : Prostate cancer
14 Rubraca : Ovarian cancer
LIST OF FIGURES
7 Figure 1: Rubraca for prostate cancer – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Rubraca for prostate cancer
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Rubraca for prostate cancer
11 Figure 4: Rubraca sales for prostate cancer across the US and five major EU markets, by country, 2017–26
23 Figure 5: Rubraca for ovarian cancer – SWOT analysis
24 Figure 6: Datamonitor Healthcare’s drug assessment of Rubraca for ovarian cancer
25 Figure 7: Datamonitor Healthcare’s drug assessment of Rubraca for ovarian cancer
LIST OF TABLES
5 Table 1: Rubraca drug profile
6 Table 2: Rubraca trials in prostate cancer
12 Table 3: Rubraca sales for prostate cancer across the US and five major EU markets, by country ($m), 2017–26
15 Table 4: Rucaparib drug profile
17 Table 5: Rubraca pivotal trial data in ovarian cancer
22 Table 6: Rubraca ongoing late-phase trials in ovarian cancer
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Relugolix 
Sign up to the